Randomized Trial for Non-small Cell Lung Cancer after Progression on EGFR TKI

Trial ID:
Michael P. Kosty, M.D.
This study will compare the safety and effectiveness of patritumab deruxtecan to standard of care platinum-based chemotherapy. Patients will be randomized (like the flip of a coin) to receive either patritumab deruxtecan or platinum-based chemotherapy and will know which treatment they are receiving. Patritumab deruxtecan is an investigational drug being used only in research.
*Have EGFR-mutated Non-small Cell Lung Cancer.<br>*Have disease progression while receiving a third-generation EGFR TKI (such as Tagrisso).<br>*Be ambulatory and able to carry out work of a light or sedentary nature. For example, must be capable of performing light housework or office work.<br>*Be willing to provide tumor tissue by either a new tumor biopsy or from a previous biopsy performed on or after treatment with EGFR TKI.

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org